Allan Rettie
Title
Cited by
Cited by
Year
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ...
New England Journal of Medicine 352 (22), 2285-2293, 2005
16902005
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
16032009
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi, DL Veenstra, LM Kondo, AK Wittkowsky, ...
Jama 287 (13), 1690-1698, 2002
13022002
The human intestinal cytochrome P450 “pie”
MF Paine, HL Hart, SS Ludington, RL Haining, AE Rettie, DC Zeldin
Drug metabolism and disposition 34 (5), 880-886, 2006
8742006
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
8702008
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
AE Rettie, KR Korzekwa, KL Kunze, RF Lawrence, AC Eddy, T Aoyama, ...
Chemical research in toxicology 5 (1), 54-59, 1992
7341992
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
KR Korzekwa, N Krishnamachary, M Shou, A Ogai, RA Parise, AE Rettie, ...
Biochemistry 37 (12), 4137-4147, 1998
6151998
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
AE Rettie, LC Wienkers, FJ Gonzalez, WF Trager, KR Korzekwa
Pharmacogenetics and Genomics 4 (1), 39-42, 1994
5991994
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ...
Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008
4772008
CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant
MG McDonald, MJ Rieder, M Nakano, CK Hsia, AE Rettie
Molecular pharmacology 75 (6), 1337-1346, 2009
3822009
Genetic association between sensitivity to warfarin and expression of CYP2C9* 3.
DJ Steward, RL Haining, KR Henne, G Davis, TH Rushmore, WF Trager, ...
Pharmacogenetics 7 (5), 361-367, 1997
3621997
Identification and functional characterization of a new CYP2C9 variant (CYP2C9* 5) expressed among African Americans
LJ Dickmann, AE Rettie, MB Kneller, RB Kim, AJJ Wood, CM Stein, ...
Molecular pharmacology 60 (2), 382-387, 2001
3392001
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral …
RL Haining, AP Hunter, ME Veronese, WF Trager, AE Rettie
Archives of Biochemistry and Biophysics 333 (2), 447-458, 1996
3311996
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics
AE Rettie, JP Jones
Annu. Rev. Pharmacol. Toxicol. 45, 477-494, 2005
3102005
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid
AE Rettie, AW Rettenmeier, WN Howald, TA Baillie
Science 235 (4791), 890-893, 1987
3061987
Developmental expression of human hepatic CYP2C9 and CYP2C19
SB Koukouritaki, JR Manro, SA Marsh, JC Stevens, AE Rettie, ...
Journal of Pharmacology and Experimental Therapeutics 308 (3), 965-974, 2004
3022004
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
DL Veenstra, JHS You, MJ Rieder, FM Farin, HW Wilkerson, DK Blough, ...
Pharmacogenetics and genomics 15 (10), 687-691, 2005
2802005
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6
W Chen, LL Koenigs, SJ Thompson, RM Peter, AE Rettie, WF Trager, ...
Chemical research in toxicology 11 (4), 295-301, 1998
2681998
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3
DH Lang, CK Yeung, RM Peter, C Ibarra, R Gasser, K Itagaki, RM Philpot, ...
Biochemical pharmacology 56 (8), 1005-1012, 1998
2621998
Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression
SB Koukouritaki, P Simpson, CK Yeung, AE Rettie, RN Hines
Pediatric research 51 (2), 236-243, 2002
2582002
The system can't perform the operation now. Try again later.
Articles 1–20